Furesi, Giulia
Zeng, Carisa https://orcid.org/0000-0002-7108-3873
Eul, Emily M.
Zarrer, Jennifer https://orcid.org/0009-0003-4264-2933
Veis, Deborah J. https://orcid.org/0000-0001-7101-5582
Ye, Jiayu
Morikis, Vasilios A.
Malachowski, Taylor
Khantakova, Darya https://orcid.org/0000-0002-2579-5140
Ulezko Antonova, Alina
Melam, Anupama https://orcid.org/0000-0002-1000-5273
Colonna, Marco https://orcid.org/0000-0001-5222-4987
Hesse, Eric https://orcid.org/0000-0002-2778-7208
Taipaleenmäki, Hanna https://orcid.org/0000-0002-8254-9333
Longmore, Gregory D. https://orcid.org/0000-0001-7568-8151
Stewart, Sheila A. https://orcid.org/0000-0002-2260-9576
Artyomov, Maxim N. https://orcid.org/0000-0002-1133-4212
Faccio, Roberta https://orcid.org/0000-0003-1639-2005
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01AR066551)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA270030)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA235096)
Siteman Investment Program, Siteman Cancer Center (Pre-R01 Program to R.F.) and the Foundation for Barnes-Jewish Hospital
Article History
Received: 12 May 2025
Accepted: 26 May 2026
First Online: 11 June 2026
Competing interests
: During the period this work was done, the Longmore laboratory received funding from Pfizer-CTI, San Diego, CA, and Centene Corporation, St. Louis, MO. M. Colonna is a member of the Vigil Neuroscientific advisory board and a consultant for Cell Signaling Technology. All other authors declare that they have no conflict of interest.